The IPH4502 dose-escalation completion is a positive catalyst, reducing some clinical risk, but the company's financing overhang (cash runway into Q3 2026 per prior 20-F) remains a key risk. Monitor year-end data readout and any subsequent financing or partnership announcements.
Price Chart
Executive Summary
Innate Pharma completed enrollment in the Phase 1 dose escalation study of IPH4502, a Nectin-4 ADC, with 76 patients enrolled and preliminary data expected by year-end. The drug shows a favorable safety profile and objective responses in heavily pre-treated patients, but the positive clinical news is tempered by the company's critical funding gap highlighted in the prior 20-F filing.
Key Facts
- Enrollment completed in Phase 1 dose escalation of IPH4502 (NCT06781983) with 76 patients.
- Preliminary data readout from 76 patients expected by year-end 2026.
- Favorable safety profile with limited hematological toxicity observed to date.
- Objective responses reported in heavily pre-treated patients with post-EV urothelial carcinoma, NSCLC, and HNSCC.
- Prior 20-F filing (April 2026) highlighted a critical funding gap and going-concern risk without immediate financing.
Financial Impact
No financial figures provided; clinical milestone with no revenue or cash impact disclosed. Prior 20-F noted cash runway into Q3 2026 and need for non-dilutive financing.
Risk Factors
- Company's cash runway ends in Q3 2026 without additional financing (per prior 20-F); dilutive offering may be needed.
- Preliminary data at year-end may not support dose optimization or further development.
- IPH4502 faces competition from approved Nectin-4 ADCs like enfortumab vedotin.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001598599-26-000008 |
| Document: a2607216kincorporatediph1.htm | 0001598599-26-000008 |
| Document: 0001598599-26-000008-index-headers.html | 0001598599-26-000008 |
| Document: 0001598599-26-000008-index.html | 0001598599-26-000008 |
| Document: 0001598599-26-000008.txt | 0001598599-26-000008 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $1.57 | awaiting T+20 | — | $1.54 (−1.91%) |
Oct 20, 2026 6d ago | 6-K | $1.58 | awaiting T+20 | — | $1.54 (−2.41%) |
Sep 17, 2026 5w ago | 6-K | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.54 (−19.37%) |
Sep 17, 2026 5w ago | 6-K | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.54 (−19.37%) |
Sep 17, 2026 5w ago | 6-K | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.54 (−19.37%) |
Sep 16, 2026 5w ago | Press Release | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.54 (−19.37%) |
Sep 10, 2026 6w ago | 6-K | $1.88 $1.48 | ▼ −21.28% | ▼ −23.40% | $1.54 (−18.09%) |
Sep 2, 2026 7w ago | 6-K | $2.17 $1.63 | ▼ −24.88% | ▼ −24.80% | $1.54 (−29.03%) |
Aug 14, 2026 10w ago | 6-K | $2.18 $1.85 | ▼ −15.14% | ▼ −13.15% | $1.54 (−29.36%) |
Aug 10, 2026 11w ago | 6-K | $2.22 $2.05 | ▼ −7.66% | ▼ −6.74% | $1.54 (−30.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers